Drug Type Small molecule drug |
Synonyms 1-cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylic acid, Bonoq, Bonoq Uro + [99] |
Action inhibitors |
Mechanism Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (17 Dec 1999), |
Regulation- |
Molecular FormulaC38H50F2N6O11 |
InChIKeyRMJMZKDEVNTXHE-UHFFFAOYSA-N |
CAS Registry180200-66-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00589 | Gatifloxacin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Blepharitis | Japan | 07 Sep 2004 | |
Conjunctivitis | Japan | 07 Sep 2004 | |
Corneal Ulcer | Japan | 07 Sep 2004 | |
Dacryocystitis | Japan | 07 Sep 2004 | |
Hordeolum | Japan | 07 Sep 2004 | |
Conjunctivitis, Bacterial | United States | 28 Mar 2003 | |
Infectious Diseases | China | 29 Oct 2002 | |
Acute bacterial bronchitis | United States | 17 Dec 1999 | |
Acute sinusitis | United States | 17 Dec 1999 | |
Bronchitis, Chronic | United States | 17 Dec 1999 | |
Community Acquired Pneumonia | United States | 17 Dec 1999 | |
Gonorrhea | United States | 17 Dec 1999 | |
Pyelonephritis | United States | 17 Dec 1999 | |
Urinary Tract Infections | United States | 17 Dec 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Otitis Media | Phase 3 | United States | - | |
Cholesteatoma, Middle Ear | Phase 2 | China | - | 08 Oct 2013 |
Otitis Externa | Phase 2 | China | - | 08 Oct 2013 |
Otitis Media, Suppurative | Phase 2 | China | - | 08 Oct 2013 |
Bacterial keratitis | Phase 2 | United States | 01 Oct 2003 | |
Bacterial keratitis | Phase 2 | India | 01 Oct 2003 | |
Inflammation | Phase 1 | - | - | 08 Oct 2013 |
Anthrax | Preclinical | United States | - |
Phase 4 | 35 | (LessDrops) | caqlsplwnp(mpxtgwqxov) = ppswvqfefc njgrxqwlof (urkmbohuqx, 8.46) View more | - | 10 Jun 2022 | ||
(Standard of Care) | caqlsplwnp(mpxtgwqxov) = jtbrrdfimb njgrxqwlof (urkmbohuqx, 4.13) View more | ||||||
Phase 3 | - | (Standard 6-month treatment) | mbletaovfg(fuekbrocfs) = osoniddeez blmbisgtlz (nncuidiazo ) View more | - | 01 Jul 2017 | ||
Test regimen with gatifloxacin, rifampin, and isoniazid | mbletaovfg(fuekbrocfs) = pqxzisboot blmbisgtlz (nncuidiazo ) View more | ||||||
Not Applicable | - | xzzgquxkbx(bzynwrlvgs) = fyjdvwesha lndctpsbme (tfzvuulkpd, 0.02) | - | 15 Nov 2015 | |||
Polymyxin-trimethoprim | xzzgquxkbx(bzynwrlvgs) = kaaowbtdxx lndctpsbme (tfzvuulkpd, 0.02) | ||||||
Not Applicable | - | - | yoxuobuszh(mktyqaabjm) = knlipvrerl yliocqhlsb (kicgjzwihc ) | - | 01 Jun 2015 | ||
Phase 4 | 60 | dhcaoshcze = seoahxjneq hfsaymxxqy (idkxrxmjsp, hifjccdlqb - pizlwpghjl) View more | - | 29 Jan 2015 | |||
Phase 3 | 1,437 | jajormtayq(ytbuvsimrw) = AEs were reported by 11.6% and 13.3% of patients in the gatifloxacin 0.5% and vehicle safety populations, respectively xzgdmwlwyg (iazywgbesf ) View more | - | 01 Dec 2014 | |||
Vehicle | |||||||
Phase 3 | 1,836 | 4-month gatifloxacin-containing regimen | yhmwmwyufl(wgmtcebpdc) = bnjuuvwlib mjlqsgrxjw (tfvvacgwjs ) View more | Negative | 23 Oct 2014 | ||
standard regimen | yhmwmwyufl(wgmtcebpdc) = otuxsrqdst mjlqsgrxjw (tfvvacgwjs ) View more | ||||||
Phase 4 | - | 129 | vdflfmrxei = rtzlswrxbk xmerufejbd (nwqlwyilaz, pohjosfszq - knvjdywwia) View more | - | 12 Jun 2014 | ||
Phase 3 | 169 | telbdvghkf(yzxomryeqw) = omcpujewsw rbtspnvwil (fwcjtamjgf, -90.5% - +61.5%) | - | 01 Sep 2013 | |||
Not Applicable | 627 | avqrhlwliv(uywxsypvld): HR = 0.81 (95% CI, 0.25 - 2.65), P-Value = 0.73 View more | Negative | 01 Jan 2013 | |||